{"id":73589,"date":"2026-04-17T16:47:05","date_gmt":"2026-04-17T11:17:05","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=73589"},"modified":"2026-04-17T16:47:08","modified_gmt":"2026-04-17T11:17:08","slug":"orchid-pharma-q4-results-2026-date-revenue-pat-amp-analyst-outlook","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/orchid-pharma-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/","title":{"rendered":"Orchid Pharma Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook"},"content":{"rendered":"<p>Orchid Pharma (NSE: ORCHPHARMA) is preparing to announce its Q4 FY26 financial results for the quarter ended March 31, 2026. With Orchid Pharma trading at Rs 680 \u2014 against a 52-week high of Rs 1,100 and a 1-year return of -32% \u2014 the Q4 FY26 results will be a pivotal event for investors tracking the Pharma sector.<\/p><p>Analyst estimates for Q4 FY26 revenue stand at Rs 220\u2013250 Cr, with PAT expectations of Rs 18\u201326 Cr and margin projections of EBITDA 14\u201318%. This article covers the Orchid Pharma Q4 results 2026 date, detailed earnings estimates, five key performance factors, five risks to monitor, analyst ratings and price targets, and answers to the most commonly searched investor questions.<\/p><p>Get free investment predictions and live Q4 result alerts on <a href=\"https:\/\/univest.in\/user\/log-in\">Univest<\/a>.<\/p><div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/orchid-pharma-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Orchid_Pharma_Q4_Results_2026_Date\" title=\"Orchid Pharma Q4 Results 2026 Date\">Orchid Pharma Q4 Results 2026 Date<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/orchid-pharma-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Why_This_Quarter_Matters\" title=\"Why This Quarter Matters\">Why This Quarter Matters<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/orchid-pharma-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Orchid_Pharma_Q4_FY26_Earnings_Estimates\" title=\"Orchid Pharma Q4 FY26 Earnings Estimates\">Orchid Pharma Q4 FY26 Earnings Estimates<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/orchid-pharma-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#5_Key_Factors_That_Will_Drive_Orchid_Pharma_Q4_FY26_Performance\" title=\"5 Key Factors That Will Drive Orchid Pharma Q4 FY26 Performance\">5 Key Factors That Will Drive Orchid Pharma Q4 FY26 Performance<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/orchid-pharma-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Revenue_Growth_Drivers_in_Pharma\" title=\"Revenue Growth Drivers in Pharma\">Revenue Growth Drivers in Pharma<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/orchid-pharma-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Margin_Recovery_and_Operating_Leverage\" title=\"Margin Recovery and Operating Leverage\">Margin Recovery and Operating Leverage<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/orchid-pharma-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#FY27_Guidance_and_Growth_Visibility\" title=\"FY27 Guidance and Growth Visibility\">FY27 Guidance and Growth Visibility<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/orchid-pharma-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Capital_Allocation_and_Balance_Sheet_Quality\" title=\"Capital Allocation and Balance Sheet Quality\">Capital Allocation and Balance Sheet Quality<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/orchid-pharma-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Competitive_Positioning_and_Market_Share\" title=\"Competitive Positioning and Market Share\">Competitive Positioning and Market Share<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/orchid-pharma-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#5_Risks_to_Watch_in_Orchid_Pharma_Q4_FY26\" title=\"5 Risks to Watch in Orchid Pharma Q4 FY26\">5 Risks to Watch in Orchid Pharma Q4 FY26<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/orchid-pharma-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Macroeconomic_Headwinds_and_Demand_Slowdown\" title=\"Macroeconomic Headwinds and Demand Slowdown\">Macroeconomic Headwinds and Demand Slowdown<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/orchid-pharma-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Input_Cost_and_Supply_Chain_Risk\" title=\"Input Cost and Supply Chain Risk\">Input Cost and Supply Chain Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/orchid-pharma-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Competitive_Pressure_and_Pricing_Risk\" title=\"Competitive Pressure and Pricing Risk\">Competitive Pressure and Pricing Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/orchid-pharma-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Regulatory_and_Compliance_Risk\" title=\"Regulatory and Compliance Risk\">Regulatory and Compliance Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/orchid-pharma-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#FY27_Guidance_Risk_and_Estimate_Cuts\" title=\"FY27 Guidance Risk and Estimate Cuts\">FY27 Guidance Risk and Estimate Cuts<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/orchid-pharma-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Orchid_Pharma_Share_Price_and_Analyst_Ratings\" title=\"Orchid Pharma Share Price and Analyst Ratings\">Orchid Pharma Share Price and Analyst Ratings<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/orchid-pharma-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/orchid-pharma-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/orchid-pharma-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#What_is_the_Orchid_Pharma_Q4_results_2026_date\" title=\"What is the Orchid Pharma Q4 results 2026 date?\">What is the Orchid Pharma Q4 results 2026 date?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/orchid-pharma-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#What_is_the_Orchid_Pharma_Q4_FY26_PAT_estimate\" title=\"What is the Orchid Pharma Q4 FY26 PAT estimate?\">What is the Orchid Pharma Q4 FY26 PAT estimate?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/orchid-pharma-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#What_is_Orchid_Pharmas_share_price_ahead_of_Q4_results\" title=\"What is Orchid Pharma&#8217;s share price ahead of Q4 results?\">What is Orchid Pharma&#8217;s share price ahead of Q4 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/orchid-pharma-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Will_Orchid_Pharma_declare_a_dividend_in_Q4_2026\" title=\"Will Orchid Pharma declare a dividend in Q4 2026?\">Will Orchid Pharma declare a dividend in Q4 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/orchid-pharma-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Which_analysts_have_a_Buy_rating_on_Orchid_Pharma\" title=\"Which analysts have a Buy rating on Orchid Pharma?\">Which analysts have a Buy rating on Orchid Pharma?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/orchid-pharma-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#What_were_Orchid_Pharma_Q3_FY26_results\" title=\"What were Orchid Pharma Q3 FY26 results?\">What were Orchid Pharma Q3 FY26 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/univest.in\/blogs-2\/orchid-pharma-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#When_do_Infosys_and_TCS_announce_Q4_results_2026\" title=\"When do Infosys and TCS announce Q4 results 2026?\">When do Infosys and TCS announce Q4 results 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/univest.in\/blogs-2\/orchid-pharma-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Is_Orchid_Pharma_a_good_investment_ahead_of_Q4_results\" title=\"Is Orchid Pharma a good investment ahead of Q4 results?\">Is Orchid Pharma a good investment ahead of Q4 results?<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/univest.in\/blogs-2\/orchid-pharma-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Recent_Article\" title=\"Recent Article\">Recent Article<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Orchid_Pharma_Q4_Results_2026_Date\"><\/span><strong>Orchid Pharma Q4 Results 2026 Date<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Company<\/strong><\/td><td><strong>Q4 FY26 Results Date<\/strong><\/td><td><strong>Sector<\/strong><\/td><\/tr><tr><td><a href=\"https:\/\/univest.in\/blogs\/tcs-q4-results-2026-date-preview\">TCS<\/a><\/td><td>April 9, 2026<\/td><td>IT Services<\/td><\/tr><tr><td><a href=\"https:\/\/univest.in\/blogs\/infosys-q4-results-2026-date-preview\">Infosys<\/a><\/td><td>April 23, 2026<\/td><td>IT Services<\/td><\/tr><tr><td>Orchid Pharma<\/td><td>May 2026 (Expected)<\/td><td>See article<\/td><\/tr><\/tbody><\/table><\/figure><p>Orchid Pharma has scheduled its Q4 FY26 results for May 2026 (Expected). The board of directors will meet on this date to approve the audited financial statements for the quarter ended March 31, 2026, and to consider a final dividend recommendation. At a CMP of Rs 680, investors will closely watch this announcement for guidance on revenue trajectory and margin outlook for FY27.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Why_This_Quarter_Matters\"><\/span><strong>Why This Quarter Matters<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Q4 FY26 is the final quarter of the financial year \u2014 it determines full-year FY26 performance, sets the FY27 estimate base, and triggers final dividend announcements. For Orchid Pharma, operating in the Pharma sector, Q4 will reveal whether earlier-quarter momentum has sustained and whether management&#8217;s strategic initiatives are translating into financial results.<\/p><p>At a 1-year return of -32%, this quarter&#8217;s results and FY27 guidance will be critical in determining whether the stock can recover to its 52-week high of Rs 1,100. Investors will focus on order book updates, margin trajectory, and capex plans \u2014 positive surprises on multiple parameters could drive meaningful re-rating.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Orchid_Pharma_Q4_FY26_Earnings_Estimates\"><\/span><strong>Orchid Pharma Q4 FY26 Earnings Estimates<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-image size-large\"><img fetchpriority=\"high\" decoding=\"async\" width=\"1024\" height=\"536\" src=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17164454\/image-1106-1024x536.jpeg\" alt=\"Orchid Pharma Q4 FY26 Earnings Estimates\" class=\"wp-image-73590\" srcset=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17164454\/image-1106-1024x536.jpeg 1024w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17164454\/image-1106-300x157.jpeg 300w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17164454\/image-1106-768x402.jpeg 768w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17164454\/image-1106-900x471.jpeg 900w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17164454\/image-1106-600x314.jpeg 600w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17164454\/image-1106-150x79.jpeg 150w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17164454\/image-1106.jpeg 1200w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure><p>Orchid Pharma Q4 FY26 Analyst Estimates at a Glance | Source: MOFSL, YES Securities, JM Financial<\/p><p>Access premium SEBI-registered research on <a href=\"https:\/\/univest.in\/user\/log-in\">Univest<\/a>.<\/p><p>Analysts covering Orchid Pharma have published Q4 FY26 estimates reflecting sector trends and company-specific catalysts. Consensus points to revenue of Rs 220\u2013250 Cr, PAT of Rs 18\u201326 Cr, and margins of EBITDA 14\u201318%. These projections incorporate seasonal Q4 strength and ongoing business improvements.<\/p><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Metric<\/strong><\/td><td><strong>Q3 FY26 Actual<\/strong><\/td><td><strong>Q4 FY26 Estimate<\/strong><\/td><\/tr><tr><td>Revenue<\/td><td>Rs 198 Cr<\/td><td>Rs 220\u2013250 Cr<\/td><\/tr><tr><td>PAT<\/td><td>Rs 14 Cr<\/td><td>Rs 18\u201326 Cr<\/td><\/tr><tr><td>Margin<\/td><td>EBITDA 15.2%<\/td><td>EBITDA 14\u201318%<\/td><\/tr><tr><td>Growth Driver<\/td><td>Base quarter<\/td><td>Recovery catalyst<\/td><\/tr><tr><td>Dividend<\/td><td>Nil<\/td><td>Nil expected<\/td><\/tr><\/tbody><\/table><\/figure><p>Beyond headline numbers, investors will monitor FY27 guidance commentary, working capital trends, and order book visibility. A clean recurring profit print \u2014 rather than one inflated by non-operational items \u2014 carries greater weight with long-term investors.<\/p><p>Screen <a href=\"https:\/\/univest.in\/screeners\">Orchid Pharma<\/a> fundamentals on <a href=\"https:\/\/univest.in\/screeners\">Univest Screener<\/a>.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"5_Key_Factors_That_Will_Drive_Orchid_Pharma_Q4_FY26_Performance\"><\/span><strong>5 Key Factors That Will Drive Orchid Pharma Q4 FY26 Performance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Revenue_Growth_Drivers_in_Pharma\"><\/span><strong>Revenue Growth Drivers in Pharma<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Orchid Pharma&#8217;s Q4 FY26 revenue of Rs 220\u2013250 Cr reflects sector-specific demand tailwinds and company-level execution. The Pharma segment is experiencing a recovery cycle driven by government policy support, consumer demand improvement, and post-pandemic normalisation. Orchid Pharma&#8217;s ability to capture this growth will depend on operational capacity, client relationships, and competitive positioning within its core markets.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Margin_Recovery_and_Operating_Leverage\"><\/span><strong>Margin Recovery and Operating Leverage<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Orchid Pharma&#8217;s Q4 FY26 margin estimate of EBITDA 14\u201318% reflects the expectation of improving operating leverage as revenues scale. Fixed cost absorption improves at higher revenue levels, and Q4&#8217;s seasonal strength is typically the most favourable quarter for margin improvement. Management&#8217;s cost discipline and pricing strategy will be key determinants of whether margins reach the upper end of analyst projections.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FY27_Guidance_and_Growth_Visibility\"><\/span><strong>FY27 Guidance and Growth Visibility<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Beyond Q4 FY26 numbers, the most consequential output from the results announcement will be FY27 guidance \u2014 revenue growth bands, margin targets, capex plans, and management commentary on macro environment. Orchid Pharma is at an inflection point where strong FY27 guidance could re-rate the stock significantly, given the current discount to its 52-week high.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Capital_Allocation_and_Balance_Sheet_Quality\"><\/span><strong>Capital Allocation and Balance Sheet Quality<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Orchid Pharma&#8217;s balance sheet health \u2014 net debt levels, working capital efficiency, and free cash flow generation \u2014 will be scrutinised in Q4 FY26 results. Strong free cash flow generation and debt reduction progress would indicate a self-funding growth model, reducing equity dilution risk and improving investor confidence in long-term value creation.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Competitive_Positioning_and_Market_Share\"><\/span><strong>Competitive Positioning and Market Share<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Orchid Pharma&#8217;s Q4 FY26 performance will reveal its competitive positioning within the Pharma sector. Market share trends, client additions, and new product\/service introductions in the quarter will inform investors about the company&#8217;s ability to sustain growth above industry averages and justify a premium over sectoral peers.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"5_Risks_to_Watch_in_Orchid_Pharma_Q4_FY26\"><\/span><strong>5 Risks to Watch in Orchid Pharma Q4 FY26<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Macroeconomic_Headwinds_and_Demand_Slowdown\"><\/span><strong>Macroeconomic Headwinds and Demand Slowdown<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The US tariff announcement in April 2026 has created global macroeconomic uncertainty affecting investor sentiment across Indian equity markets. For Orchid Pharma, indirect impacts include FII outflows, demand softness in export markets, and elevated input costs if global commodity prices remain elevated. Any deterioration in macro conditions for FY27 would require analyst estimate cuts.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Input_Cost_and_Supply_Chain_Risk\"><\/span><strong>Input Cost and Supply Chain Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Orchid Pharma is exposed to input cost volatility through its supply chain. Raw material price increases, logistics disruptions, or supply shortages \u2014 whether domestic or global \u2014 could compress margins and delay revenue recognition. Management&#8217;s ability to pass through cost increases to customers is a key differentiator between margin recovery and margin disappointment in Q4 FY26.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Competitive_Pressure_and_Pricing_Risk\"><\/span><strong>Competitive Pressure and Pricing Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The Pharma sector is experiencing intensifying competition from both established players and new entrants. Pricing pressure from competitors could force Orchid Pharma to offer discounts or invest more in customer acquisition, both of which compress margins. Any market share loss to competitors in Q4 FY26 would be viewed negatively by analysts.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Regulatory_and_Compliance_Risk\"><\/span><strong>Regulatory and Compliance Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Changes in government policy, regulatory requirements, or compliance standards in the Pharma sector could increase costs or disrupt business operations. SEBI, GST, environmental, or sector-specific regulations represent ongoing compliance requirements that could generate unexpected liabilities.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FY27_Guidance_Risk_and_Estimate_Cuts\"><\/span><strong>FY27 Guidance Risk and Estimate Cuts<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>If Orchid Pharma&#8217;s FY27 guidance falls below Street expectations \u2014 even if Q4 FY26 numbers are in line \u2014 the stock could decline significantly. The market prices forward earnings, and any negative guidance revision would trigger analyst estimate cuts and multiple compression. Management&#8217;s credibility on guidance delivery is therefore as important as the Q4 numbers themselves.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Orchid_Pharma_Share_Price_and_Analyst_Ratings\"><\/span><strong>Orchid Pharma Share Price and Analyst Ratings<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"536\" src=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17164648\/Orchid-Share-Price-Snapshot-1024x536.jpg\" alt=\"Orchid Pharma Share Price and Analyst Ratings\" class=\"wp-image-73595\" srcset=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17164648\/Orchid-Share-Price-Snapshot-1024x536.jpg 1024w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17164648\/Orchid-Share-Price-Snapshot-300x157.jpg 300w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17164648\/Orchid-Share-Price-Snapshot-768x402.jpg 768w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17164648\/Orchid-Share-Price-Snapshot-900x471.jpg 900w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17164648\/Orchid-Share-Price-Snapshot-600x314.jpg 600w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17164648\/Orchid-Share-Price-Snapshot-150x79.jpg 150w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17164648\/Orchid-Share-Price-Snapshot.jpg 1200w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure><p>Orchid Pharma Share Price &amp; Analyst Ratings | Source: NSE\/BSE, Broker Notes<\/p><p>Orchid Pharma is trading at Rs 680 as of early April 2026, against a 52-week high of Rs 1,100 and 52-week low of Rs 540. Market cap stands at Rs 2,600 Cr. The 1-year return of -32% reflects both sector headwinds and company-specific factors. Analyst price targets diverge based on views on recovery pace and FY27 earnings potential.<\/p><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Brokerage<\/strong><\/td><td><strong>Rating<\/strong><\/td><td><strong>Target Price<\/strong><\/td><td><strong>Thesis<\/strong><\/td><\/tr><tr><td>MOFSL<\/td><td>Buy<\/td><td>Rs 850<\/td><td>Cephalosporin turnaround<\/td><\/tr><tr><td>YES Securities<\/td><td>Buy<\/td><td>Rs 900<\/td><td>ANDA approvals pipeline<\/td><\/tr><tr><td>JM Financial<\/td><td>Neutral<\/td><td>Rs 750<\/td><td>Debt reduction watch<\/td><\/tr><\/tbody><\/table><\/figure><p>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Orchid Pharma&#8217;s live price and receive real-time Q4 result alerts.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Orchid Pharma Q4 FY26 results will reflect the ongoing cephalosporin API business turnaround. At Rs 680 \u2014 38% below its 52-week high \u2014 the stock prices in significant execution risk. A PAT of Rs 22 Cr+ combined with new ANDA filing announcements would signal that the recovery story is on track. Debt reduction progress is equally important for improving investor confidence. Consult a SEBI-registered advisor before investing.<\/p><p>This content is published by Univest, a SEBI-registered research and advisory platform. All analyst estimates and price targets cited are from publicly available broker notes. Past performance is not indicative of future results. Investors should conduct independent due diligence before making any investment decisions.<\/p><p>For more Q4 FY26 previews across IT, banking, auto, pharma, and cement sectors, visit <a href=\"https:\/\/univest.in\/blogs\">Univest Blogs<\/a>.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_the_Orchid_Pharma_Q4_results_2026_date\"><\/span><strong>What is the Orchid Pharma Q4 results 2026 date?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Orchid Pharma Q4 FY26 results are scheduled for May 2026 (Expected). The board will meet to approve audited financial statements and consider a dividend recommendation for FY26.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_the_Orchid_Pharma_Q4_FY26_PAT_estimate\"><\/span><strong>What is the Orchid Pharma Q4 FY26 PAT estimate?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Analysts estimate Orchid Pharma Q4 FY26 net profit (PAT) in the range of Rs 18\u201326 Cr, based on revenue of Rs 220\u2013250 Cr and margin of EBITDA 14\u201318%. Actual results may differ from consensus estimates.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_Orchid_Pharmas_share_price_ahead_of_Q4_results\"><\/span><strong>What is Orchid Pharma&#8217;s share price ahead of Q4 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Orchid Pharma shares are trading at approximately Rs 680 as of early April 2026. The 52-week high is Rs 1,100 and 52-week low is Rs 540. The one-year return is -32% and market cap stands at Rs 2,600 Cr.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Will_Orchid_Pharma_declare_a_dividend_in_Q4_2026\"><\/span><strong>Will Orchid Pharma declare a dividend in Q4 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Orchid Pharma is expected to consider a dividend of Nil expected at the Q4 FY26 board meeting on May 2026 (Expected). This signals management&#8217;s confidence in FY26 free cash flow generation.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Which_analysts_have_a_Buy_rating_on_Orchid_Pharma\"><\/span><strong>Which analysts have a Buy rating on Orchid Pharma?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>MOFSL (target Rs 850), YES Securities (target Rs 900) have positive ratings on Orchid Pharma ahead of Q4 FY26 results.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_were_Orchid_Pharma_Q3_FY26_results\"><\/span><strong>What were Orchid Pharma Q3 FY26 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>In Q3 FY26, Orchid Pharma reported revenue of Rs 198 Cr and PAT of Rs 14 Cr, with margins at EBITDA 15.2%. These provided the base for Q4 FY26 analyst estimates.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"When_do_Infosys_and_TCS_announce_Q4_results_2026\"><\/span><strong>When do Infosys and TCS announce Q4 results 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>TCS announced Q4 FY26 results on April 9, 2026 \u2014 see the full <a href=\"https:\/\/univest.in\/blogs\/tcs-q4-results-2026-date-preview\">TCS Q4 Results 2026<\/a> preview. <a href=\"https:\/\/univest.in\/blogs\/infosys-q4-results-2026-date-preview\">Infosys<\/a> announced Q4 FY26 results on April 23, 2026.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Is_Orchid_Pharma_a_good_investment_ahead_of_Q4_results\"><\/span><strong>Is Orchid Pharma a good investment ahead of Q4 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Orchid Pharma at Rs 680 offers a risk-reward contingent on Q4 execution and FY27 guidance. Investors should review analyst estimates and consult a SEBI-registered advisor before making investment decisions.<\/p><p>Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All financial data and analyst estimates are sourced from publicly available information including NSE\/BSE filings and company investor relations pages. Verify all numbers before investing. Consult a SEBI-registered advisor before making investment decisions.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Recent_Article\"><\/span><strong>Recent Article<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/blogs\/motisons-jewellers-q4-results-2026\">Motisons Jewellers Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/motilal-oswal-financial-services-q4-results-2026\">Motilal Oswal Financial Services Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/moschip-technologies-q4-results-2026\">Moschip Technologies Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/morepen-laboratories-q4-results-2026\">Morepen Laboratories Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/morarjee-textiles-q4-results-2026\">Morarjee Textiles Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Orchid Pharma (NSE: ORCHPHARMA) is preparing to announce its Q4 FY26 financial results for the quarter ended March 31, 2026. With Orchid Pharma trading at Rs 680 \u2014 against a 52-week high of Rs 1,100 and a 1-year return of -32% \u2014 the Q4 FY26 results will be a pivotal event for investors tracking the<\/p>\n","protected":false},"author":27,"featured_media":73593,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802,3862],"class_list":["post-73589","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news","tag-q4-results-expectations"],"metadata":{"_edit_lock":["1776427704:27"],"_last_editor_used_jetpack":["block-editor"],"rank_math_internal_links_processed":["1"],"amazonS3_cache":["a:8:{s:63:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/image-1106.jpeg\";a:2:{s:2:\"id\";i:73590;s:11:\"source_type\";s:13:\"media-library\";}s:72:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/image-1106-1024x536.jpeg\";a:2:{s:2:\"id\";i:73590;s:11:\"source_type\";s:13:\"media-library\";}s:95:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17164454\/image-1106.jpeg\";a:2:{s:2:\"id\";i:73590;s:11:\"source_type\";s:13:\"media-library\";}s:104:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17164454\/image-1106-1024x536.jpeg\";a:2:{s:2:\"id\";i:73590;s:11:\"source_type\";s:13:\"media-library\";}s:79:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/Orchid-Share-Price-Snapshot.jpg\";a:2:{s:2:\"id\";i:73595;s:11:\"source_type\";s:13:\"media-library\";}s:88:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/Orchid-Share-Price-Snapshot-1024x536.jpg\";a:2:{s:2:\"id\";i:73595;s:11:\"source_type\";s:13:\"media-library\";}s:111:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17164648\/Orchid-Share-Price-Snapshot.jpg\";a:2:{s:2:\"id\";i:73595;s:11:\"source_type\";s:13:\"media-library\";}s:120:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17164648\/Orchid-Share-Price-Snapshot-1024x536.jpg\";a:2:{s:2:\"id\";i:73595;s:11:\"source_type\";s:13:\"media-library\";}}"],"rank_math_primary_category":["842"],"rank_math_seo_score":["83"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"rank_math_focus_keyword":["Orchid Pharma"],"rank_math_title":["Orchid Pharma Q4 Results 2026: Date, Revenue &amp; ANDA Pipeline"],"rank_math_description":["Orchid Pharma Q4 FY26 results expected May 2026. Revenue estimate Rs 220\u2013250 Cr, PAT Rs 18\u201326 Cr. Cephalosporin API turnaround preview with analyst targets.\n"],"_thumbnail_id":["73593"],"_edit_last":["27"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["8443"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17164513\/Orchid-Pharma-Q4-FY26-Preview.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/73589","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/27"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=73589"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/73589\/revisions"}],"predecessor-version":[{"id":73596,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/73589\/revisions\/73596"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/73593"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=73589"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=73589"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=73589"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}